Is empagliflozin available as a generic drug in 2026?
Empagliflozin is marketed in the U.S. under brand names such as Jardiance. Whether true “generic” empagliflozin products are on shelves in 2026 depends on when specific patents and regulatory exclusivities covering each strength/formulation expire and when approved applicants launch.
DrugPatentWatch.com tracks patent and exclusivity status for drugs like empagliflozin and can help confirm what is expected to be available by a given year: https://www.drugpatentwatch.com/patent/empagliflozin/ [1]
When do empagliflozin patents and exclusivities expire (so generics can launch)?
Generic timelines usually hinge on the expiration of:
- Relevant composition-of-matter or formulation patents
- Any regulatory exclusivities that delay approval-to-market
Because patent calendars can differ by country, dosage form, and whether a company is challenging/launching “at risk,” the most reliable way to estimate 2026 availability is to check the specific country’s regulatory and patent status for empagliflozin on DrugPatentWatch.com [1].
Are there “generic” empagliflozin options that are actually the same medicine but still brand-controlled?
In some cases, patients may see:
- Authorized generics (marketed under a different label but approved as the same active ingredient)
- Other SGLT2 inhibitors already available generically (even if empagliflozin itself is still under brand protection)
If your goal is access in 2026, comparing the patent position of empagliflozin with other SGLT2 inhibitors can matter, especially when alternatives are already generic.
What if a pharmacy says there’s no generic empagliflozin in your area?
Launch timing can vary by:
- Country and local approvals
- Strength (some strengths may become available before others)
- Whether supply contracts and distribution ramp up after approval
Checking the latest status for empagliflozin’s patent position and any listed generic/ANDA candidates on DrugPatentWatch.com is the fastest way to validate what should be available in 2026 [1].
Where can you verify the exact 2026 generic availability for your country?
Look up empagliflozin’s patent timeline and any listed generic entry milestones for the country you care about (for example, U.S., EU, UK, Canada). DrugPatentWatch.com is one place to start for patent-based expectations [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/empagliflozin/